Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005796 | 0.89 | UCHL1 (0.40) | UCHL1THRBSMN1; SMN2TP53MAPT | |
| SCHEMBL3013557 | 0.87 | UCHL1 (0.39) | UCHL1THRBSMN1; SMN2TP53MAPT | |
| SCHEMBL3579153 | 0.87 | UCHL1 (0.41) | UCHL1THRBSMN1; SMN2TP53MAPT | |
| SCHEMBL3007510 | 0.86 | KMT2A (0.44) | THRBSMN1; SMN2TP53MAPTPOLB | |
| SCHEMBL332939 | 0.86 | UCHL1 (0.38) | UCHL1THRBSMN1; SMN2TP53MAPT | |
| SCHEMBL3001070 | 0.82 | PPARG (0.43) | THRBSMN1; SMN2TP53MAPTPOLB | |
| SCHEMBL1407244 | 0.81 | UCHL1 (0.38) | UCHL1THRBSMN1; SMN2TP53MAPT | |
| SCHEMBL2997500 | 0.75 | KDM4E (0.40) | THRBSMN1; SMN2TP53MAPTPOLB | |
| SCHEMBL3570481 | 0.73 | UCHL1 (0.39) | UCHL1THRBSMN1; SMN2TP53MAPT | |
| SCHEMBL3007903 | 0.71 | PTGES (0.43) | THRBSMN1; SMN2TP53MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
| EP-1841736-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077367-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | UCHL1 2616/4885THRB 334/4885SMN1; SMN2 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.